Atlas Trials

Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19

Clinical trial NCT05639166 · COMPLETED

Trial details

NCT number
NCT05639166
Sponsor
Immune Biosolutions Inc
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
COVID-19
Start date
2023-02-18
Primary completion
2023-05-16
Enrollment
200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.